OBJECTIVES: Rapid deployment aortic valve replacement (AVR) has been developed to facilitate minimally invasive approaches for cardiac surgery and shorten procedural times. TRITON is a prospectively designed study to assess safety and efficacy of rapid deployment AVR with Edwards INTUITY valve system. This report presents the 5-year outcomes of the TRITON trial.
INTRODUCTION
Aortic valve replacement (AVR) with rapid deployment valves is intended to facilitate minimally invasive surgery and reduce procedural and implant time [1] . The Edwards INTUITY valve system (Edwards Lifesciences LLC, Irvine, CA, USA) is a rapid deployment aortic valve built on the design of the Carpentier-Edwards Perimount Magna Ease platform (Edwards Lifesciences LLC), and includes a balloon-expandable stainless steel frame similar to the frame structure of the Sapien transcatheter aortic heart valve (Edwards Lifesciences LLC). The TRITON trial was prospectively designed to evaluate the safety and performance of the INTUITY valve system over 5 years of patient follow-up.
In addition to the TRITON trial, the clinical experience with Edwards INTUITY was evaluated in a prospective, multicentre, randomized comparison trial (CADENCE-MIS, NCT02672553) and 1 European registry (FOUNDATION, NCT02338154) [2, 3] . Early (30 days) and mid-term (3 years) results of the TRITON trial have been published previously and indicate that rapid deployment AVR with Edwards INTUITY results in excellent safety and haemodynamic performance up to 3 years [4] [5] [6] . In this report, we present 5 years clinical outcomes of isolated AVR (iAVR) and AVR performed with other concomitant procedures (cAVR).
MATERIALS AND METHODS

Study design and study population
The TRITON study is a prospective, multicentre trial conducted in 6 German and Austrian hospitals designed to follow patients for 5 years after AVR with the Edwards INTUITY system. The TRITON trial was conducted as part of CE-mark approval. The detailed study design and methods have been previously described [4] [5] [6] . Patient solicitation for participation in this study was based upon selection by the surgeon, which in turn was based upon an appropriate patient risk profile and surgeon preference. A total of 295 patients were enrolled and 287 patients received the Edwards INTUITY valve system by either full sternotomy or minimally invasive surgery (Fig. 1) . All presented data are based on a database lock date of 1 July 2016.
The study protocol was reviewed and approved by regulatory authorities (BfArM, AGES), the Ethics Committee of each participating centre, and all patients provided written informed consent before any study activities. The study is listed on ClinicalTrials.gov NCT01445171.
Rapid deployment aortic valve replacement
The Edwards INTUITY valve systems used in the study were the Model 8300ACA (Generation I; CE-certified April 2011) and Model 8300ACB (Generation II, pre-CE certified device) [2] [3] [4] [5] [6] . A detailed description is given in the Supplementary material. The first 149 patients were enrolled to receive Edwards INTUITY Generation I between January 2010 and March 2012. Overall, 138 patients received Edwards INTUITY Generation II and were enrolled between November 2011 and October 2012.
Postoperative care and follow-up
Anticoagulant therapy was given to patients, except when contraindicated, for 3 months post-valve implant in accordance with published guidelines [7] . Procedural, early (< _30 days) and longterm outcomes were collected and evaluated at 3 months, and thereafter annually from 1 to 5 years. Haemodynamic performance was evaluated at discharge, 3 and 12 months and then annually for up to 5 years by an independent Echocardiography Core Laboratory in accordance with published guidelines [8] . All safety end-points and serious adverse events were adjudicated by an independent Clinical Events Committee (CEC), as per Akins guidelines [9] .
End-points
Primary safety end-points included valve-related mortality, valve thrombosis, thromboembolic events, major bleeding events, paravalvular leakage (PVL) and study valve-related endocarditis. Additional secondary safety end-points were assessed including all-cause mortality, cardiovascular related mortality, study valve structural deterioration, explant/reoperation, haemolysis, new pacemaker implant. Definitions of the safety end-points were based on Akins Guidelines and are described in Supplementary material. In addition, several performance end-points were collected, including improvement in NYHA functional class and haemodynamic performance by echocardiography.
Data management and statistical analysis
Edwards Lifesciences, as study sponsor, managed the collection and monitoring of data. The final interpretation of end-points was done by the CEC. All results are analysed on an 'as treated' basis, meaning all patients who received an Edwards INTUITY valve ( Fig. 1 ; Study Group INTUITY).
Patient baseline demographics and early (< _30 days after the index procedure) safety and efficacy end-points are given as either continuous or categorical variables and long-term (>30 days and up to 5 years) safety end-points were analysed using linearized rates (percent per patient year = %/ppy) and/or the KaplanMeier method with 95% confidence intervals (CIs). All type of early and late mortality as well as safety end-points are stratified by type of AVR surgery (iAVR and cAVR). Continuous variables are shown as mean values with standard deviation. Categorical variables are expressed as percentages and number of patients. If not otherwise indicated, statistical inferences comparing continuous variables were made using a Wilcoxon-Mann-Whitney tests. Comparisons of categorical variables were routinely made using Pearson's chi-square test; however when the outcome in any group was less than 5, Fisher's exact test was used. Two-sided tests were utilized and a type I error significance level of 0.05 was considered significant.
RESULTS
Baseline patient characteristics and procedural outcomes
Of 295 enrolled patients, 287 (97.3%) were successfully implanted with the study valve; 8 patients were not implanted with the study valve, for different reasons (adverse anatomical situation during implant and/or proper valve size not available). Baseline characteristics for the study valve patients are presented in Table 1 . iAVR and cAVR were performed in 158 (55.1%) and 129 (44.9%) patients, respectively. Procedural and discharge outcomes have been reported previously [5] . Briefly, cross-clamp times were 52.8 ± 26.0 min and cardiopulmonary bypass times 84.6 ± 36.9 min.
The concomitant procedures of cAVR patients (n = 129) included coronary artery bypass grafting (n = 78), or other procedures (n = 51) such as atrial ablation (n = 16), septal myectomy (n = 4), aortic aneurysm/dissection repair (n = 4). Across all study valve patients, valve size distribution was as follows: 19 mm (n = 6), 21 mm (n = 85), 23 mm (n = 99), 25 mm (n = 78) and 27 mm (n = 19).
Clinical outcomes
Mean patient follow-up was 3.7 ± 1.4 years with 89 patients reaching 5 years corresponding to a total of 1050 late patient years of follow-up. Early and late end-points are summarized in Table 2 .
Mortality. Early all-cause mortality was 1.7% (n = 5: cardiac failure (3), myocardial infarction (1), multi-organ failure (1); 3 (1.0%) of these 5 deaths have been CEC-adjudicated as valve-related (iAVR n = 2, cAVR n = 1). We observed a late event rate for all-cause death of 3.5%/ppy (37 events). A total of 16 late-deaths (2.7%/ppy) occurred for iAVR and 21 events (4.5%/ppy) for cAVR. Causes for all-cause late mortality were evaluated and adjudicated by the CEC as cardiac arrest/failure (7), pulmonary dysfunction/failure (7), infection (4), major bleeding (2), myocardial infarction (2), multiorgan failure (2), renal failure (2), vascular aneurysm (2), thromboembolic event (1), endocarditis (1), sudden unexplained death (1), other reason (6) . Two of the events were categorized as valverelated (iAVR n = 1, cAVR n = 1, Table 2 ). Survival rate for all patients was 81.1% (95% CI: 75.5-86.8%) at 5 years (Fig. 2) . iAVR patients had a survival rate of 85.7% (95% CI: 79.2-92.3%); cAVR subjects had a survival rate of 75.2% (95% CI: 65.6-84.8%; Pvalue = 0.085).
Thromboembolic events. Thirteen (4.5%) early thromboembolic events and 18 (1.7%/ppy) late thromboembolic events were identified. The majority of these events were stroke (11/18 events); this represents 1.0%/ppy.
Bleeding. There were 22 early (7.3%) and 23 late (2.2%/ppy) major bleeding events identified. Overall, 11/22 of the early and 12/23 of the late events were anticoagulation related. Early event rate in iAVR and cAVR patients was 7.6% and 7.0%, respectively. There were 14 late bleeding events in iAVR patients (2.4%/ppy) and 9 events in cAVR patients (1.9%/ppy).
Valve explant/reoperation. The study valve was explanted early in 4 (1.4%) patients (3 iAVR and 1 cAVR) and late in 5 patients (iAVR: 0.2%/ppy, cAVR: 0.9%/ppy). All of these cases were non-fatal. The reasons for the early explants were due to procedural bleeding (n = 1), cardiac arrest (n = 1) after 2 days and PVL (n = 2) at 19 and 26 days. The reasons for the late explants were due to endocarditis (n = 1), pseudoaneurysm at the annulus (n = 1) and PVL (n = 3). To date, no valve has been explanted due to structural valve deterioration.
Structural valve deterioration. Four (0.4%/ppy) late events of structural valve deterioration (iAVR: n = 2, cAVR: n = 2) were identified presenting as prosthesis stenosis.
Endocarditis. At late follow-up, 2 events of endocarditis were identified. One event resulted in valve explant and the other one was successfully treated by medication. by the Echocardiography Core Laboratory, was detected early in 2 (0.7%) and late in 7 (0.7%/ppy) patients.
Pacemaker implantation. New pacemakers were implanted in 19 (6.9%) patients before 30 days follow-up and in 17 (1.6%/ ppy) cases during the later follow-up (Table 2) .
NYHA functional class. At 5 years, 63.2% of the patients showed a sustained improvement of NYHA classification, while 25.3% of the patients remained in the same NYHA class (Fig. 3) . 
Haemodynamic outcome
Detailed haemodynamic outcomes are shown in Table 3 . The mean effective orifice area (EOA) at 3 and 5 years was 1.7 ± 0.2 cm 2 and 1.6 ± 0.3 cm 2 , respectively, across all valve sizes. The mean gradient at 1 year was 9.0 ± 3.5 mmHg, at 3 years it was 9.6 ± 4.3 mmHg and at 5 years it was 10.5 ± 5.4 mmHg across all valve sizes (n = 59). Left ventricular mass at 1 year (n = 178) was 184 ± 48 g, at 3 years (n = 135) it was 187 ± 48 g and at 5 years (n = 34) it was 192 ± 44 g. In comparison to preoperative baseline (233 ± 62 g), the 5-year left ventricular mass remained significantly reduced (P = 0.008). Cases of patient prosthesis mismatch (PPM) at 5 years are presented in Table 4 . Overall, 64.7% of the patients were free from PPM. In total, 7.8% (n = 4/51) of the patients had a severe PPM as defined by EOA index <0.65 cm 2 /m 2 .
DISCUSSION
This is the first report of 5-year results of the TRITON trial presenting the long-term safety and efficacy of rapid deployment The 5-year survival rate was 85.7% for iAVR patients and 75.2% for cAVR patients. The trend towards better long-term survival in the iAVR group was due to significantly reduced late cardiovascular mortality in the iAVR. In the TRITON trial, overall survival at 5 years was 81.1%. Studies evaluating the safety and efficacy of sutureless valves (Perceval) report a cumulative survival curve at 4 years of approximately 70% [12] or at 5 years around 75% [13] .
However, in the Perceval study comprising 731 patients only 2 patients were at risk after 5 years [13] . Survival rate presented for the 3f Enable valve, another rapid deployment valve, at 5 years was 77% with 24 patients being at risk [11] . These low numbers of patients at risk after 5 years display a certain weakness of available long-term data for other sutureless valves. Nevertheless, the observed differences in favour of INTUITY could also be attributed to an older patient population in Perceval studies (79 ± 5.3 or 78.5 ± 5.3 years) in comparison to the TRTION study (76.1 ± 5.7 years) and 3f Enable study (75.3 ± 6.7 years).
Due to its unique anchoring mechanism, the question of longterm stability at the level of ventriculo-arterial junction and left ventricular outflow tract and thus PVL is relevant. We found low early (0.7%) and late (0.7%/ppy) rates of major PVL, as well as rates for all late PVL (iAVR 4.1%/ppy; cAVR 4.5%/ppy) that are comparable to published data for conventional AVR (3.1-6%) [14, 15] . These data support the concept that tissue ingrowth in the stent frame with robust sealing of the anchoring zone occurs and contributes to a low overall PVL rate. This is the first time that 5 years haemodynamic data for Edwards INTUITY valve system are reported. Consistent excellent EOA and low gradients up to 5 years were observed during the TRITON study. It should be emphasized that the favourable EOA with low mean and peak gradients are based on a relatively high number of investigated patients (n = 57, 59 and 59) and show the sustained benefit of the Edwards INTUITY valve for patients up to 5 years. The rate of severe PPM was always in the single digit range (2.4-7.8%). Theron et al. [16] published previously a subset of patients with Edwards INTUITY valve sizes of 19 and 21 mm in a single centre study with a 15% rate of severe PPM at 30 days. This also underscores the highly favourable haemodynamic performance of the Edwards INTUITY valve and is explained by the lack of suture material and pledgets [17] . PPM is also a relevant issue in the context of transcatheter aortic valve implantation (TAVI) valves. Recently a meta-analysis by Takagi et al. [18] for the ALICE group found an 8% severe PPM rate early (mostly 30 days) after TAVI suggesting superiority over conventional aortic valves. In contrast the INTUITY valve in our study demonstrates a distinctly lower severe PPM rate of 2.4-3.9% up to 3 years. Although this comparison might be methodologically challenged we speculate that the newer generation of surgical valves offer improved haemodynamic performance over TAVI valves.
Clinical and sub-clinical prosthetic valve thrombosis has recently attracted interest for TAVI and surgical aortic valve replacement alike [19, 20] . The prevalence of this phenomenon seems to be higher for TAVI [19, 21] but it also deserves attention for surgical AVR and newer types of AVR prostheses [22] . Early and late valve thrombosis in the current study was 0%. While clinical valve thrombosis is completely absent in the setting of the TRITON study, sub-clinical valve thrombosis cannot be ruled out completely. Corresponding with these findings, a low 1.7%/ ppy rate of late thromboembolic events was observed.
Prosthetic endocarditis is a further major safety issue and the INTUITY valve had a remarkably low early and late rate of 0.2% and 0.2%/ppy, respectively. Regueiro et al. [23] found a 1.1%/ppy rate of prosthethic endocarditis after TAVI in 'The Infectious Endocarditis after TAVR International Registry' which included TAVI patients with definite infective endocarditis from 47 centres. This is remarkably higher than the rates in our long-term study and documents another benefit of rapid deployment valves.
Finally the Edwards INTUITY shows acceptable early pacemaker implantation rate of 5.3% for iAVR and 9.0% for cAVR patients. Both groups were within the range of the surgical valve literature, which is reported between 3.0% and 11.8% [24] . Previous studies of Carpentier-Edwards Perimount valves have reported a rate of new permanent pacemaker implantation of 9.5% with minimally invasive surgery approaches and 5.2% in full sternotomy cases [25] .
Limitations
Regarding limitations, TRITON lacks a control group. During enrolment, there might have been selection and channelling biases, despite the fact that the definition of clinical end-points was a priori.
CONCLUSIONS
In summary, 5-year clinical outcomes indicate the safety of rapid deployment AVR with the Edwards INTUITY valve system, based especially on substantive data over the late follow-up period. Haemodynamic measures exhibited low gradient and solid EOA through 5 years, as well as a significant and sustained decrease in left ventricular mass. Severe PPM, clinical valve thrombosis and endocarditis were particularly low. Rates of PVL and new pacemaker implants were within clinically acceptable rates. The Edwards INTUITY system demonstrates desirable long-term outcomes and a quite satisfactory safety profile. 
